An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial

Anthony Cahn, J. Hamblin, Jon Robertson, Malcolm Begg, Emily Jarvis, Robert C. Wilson, Gordon J. Dear, Claudia Leemereise, Yi Cui, Maki Mizuma, Mickaël Montembault, Cedric Van Holsbeke, Wim Vos, Wilfried De Backer, Jan De Backer, Edith M. HesselInternational Journal of COPD 2021 · DOI

Abstract

These data show that addition of nemiralisib to usual care delivers more effective recovery from an acute exacerbation and improves lung function parameters including siVaw and FEV<sub>1</sub>. Although post-inhalation cough was identified, nemiralisib was otherwise well tolerated, providing a promising novel therapy for this acutely ill patient group.
BibTeX
@article{cahn2021inhaled,
  author = {Anthony Cahn and J. Hamblin and Jon Robertson and Malcolm Begg and Emily Jarvis and Robert C. Wilson and Gordon J. Dear and Claudia Leemereise and Yi Cui and Maki Mizuma and Mickaël Montembault and Cedric Van Holsbeke and Wim Vos and Wilfried De Backer and Jan De Backer and Edith M. Hessel},
  title = {{An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial}},
  journal = {International Journal of COPD},
  year = {2021},
  doi = {10.2147/copd.s309129},
}

Loading related content...

Figure